1.Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE et al: Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2011, 52(3):e18–55.
2.Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clinical pharmacokinetics 2004, 43(13):925–942.
3.Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP: Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2009, 49(3):325–327.
4.Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R: Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrobial agents and chemotherapy 2009, 53(2):428–434.
5.Romano S, Fdez de Gatta MM, Calvo MV, Caballero D, Dominguez-Gil A, Lanao JM: Population pharmacokinetics of amikacin in patients with haematological malignancies. The Journal of antimicrobial chemotherapy 1999, 44(2):235–242.
6.Buelga DS, del Mar Fernandez de Gatta M, Herrera EV, Dominguez-Gil A, Garcia MJ: Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies. Antimicrobial agents and chemotherapy 2005, 49(12):4934–4941.
7.Fernandez de Gatta Mdel M, Santos Buelga D, Sanchez Navarro A, Dominguez-Gil A, Garcia MJ: Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/pharmacodynamic analysis. Clinical pharmacokinetics 2009, 48(4):273–280.
8.He J, Mao EQ, Feng J, Jiang HT, Yang WH, Chen EZ: The pharmacokinetics of vancomycin in patients with severe acute pancreatitis. European journal of clinical pharmacology 2016, 72(6):697–702.
9.Martin JH, Norris R, Barras M, Roberts J, Morris R, Doogue M, Jones GR: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. The Clinical biochemist Reviews 2010, 31(1):21–24.
10.Khwaja A: KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical practice 2012, 120(4):c179–184.
11.Ye ZK, Chen YL, Chen K, Zhang XL, Du GH, He B, Li DK, Liu YN, Yang KH, Zhang YY et al: Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. The Journal of antimicrobial chemotherapy 2016, 71(11):3020–3025.
12.Sadoh S, Tsuji Y, Tsukamoto K: [Correlation of pharmacokinetic parameters with serum vancomycin concentration in elderly patients with malignancies]. Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan 2010, 130(1):69–73.
13.Chang D: Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. The Pediatric infectious disease journal 1995, 14(8):667–673.
14.Omote S, Yano Y, Hashida T, Masuda S, Yano I, Katsura T, Inui K: A retrospective analysis of vancomycin pharmacokinetics in Japanese cancer and non-cancer patients based on routine trough monitoring data. Biological & pharmaceutical bulletin 2009, 32(1):99–104.
15.Balkwill F: Tumour necrosis factor and cancer. Nature reviews Cancer 2009, 9(5):361–371.
16.Shimada I, Iwata C, Taga S, Teramachi H, Nomura M, Miyamoto K, Tsuciya H, Wada T, Kimura K, Matsushita R: Enhanced renal clearance of vancomycin in rats with carcinogen-induced osteosarcoma. Anticancer research 2012, 32(3):823–829.
17.Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D: Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive care medicine 2013, 39(7):1247–1252.
18.del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, Dominguez-Gil A, Sanchez Navarro A: Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive care medicine 2007, 33(2):279–285.
19.Udy AA, Roberts JA, Lipman J: Implications of augmented renal clearance in critically ill patients. Nature reviews Nephrology 2011, 7(9):539–543.
20.He J, Mao E, Jing F, Jiang H, Yang W, Chen E: [Pharmacokinetics of vancomycin in patients with severe acute pancreatitis and its influencing factors: analysis of 7 years data]. Zhonghua wei zhong bing ji jiu yi xue 2017, 29(6):491–495.
21.Curth HM, Pelc A, Kutting F, Steffen HM: Augmented renal vancomycin clearance in cancer patients: a case report and review of the literature. Oncology research and treatment 2015, 38(4):182–184.
22.Randers E, Erlandsen EJ: Serum cystatin C as an endogenous marker of the renal function—a review. Clinical chemistry and laboratory medicine 1999, 37(4):389–395.
23.Fliser D, Ritz E: Serum cystatin C concentration as a marker of renal dysfunction in the elderly. American journal of kidney diseases: the official journal of the National Kidney Foundation 2001, 37(1):79–83.
24.Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ, Brunner N: Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clinical cancer research: an official journal of the American Association for Cancer Research 2000, 6(2):505–511.
25.Yang F, Li D, Di Y, Zhang Y, Zang Y, Ren J, Yan L, Zhou Z, Liu H, Xu Z: Pretreatment Serum Cystatin C Levels Predict Renal Function, but Not Tumor Characteristics, in Patients with Prostate Neoplasia. BioMed research international 2017, 2017:7450459.
26.Ohara G, Miyazaki K, Kurishima K, Kagohashi K, Ishikawa H, Satoh H, Hizawa N: Serum levels of cystatin C in elderly lung cancer patients. Oncology letters 2012, 3(2):303–306.
27.Frazee E, Rule AD, Lieske JC, Kashani KB, Barreto JN, Virk A, Kuper PJ, Dierkhising RA, Leung N: Cystatin C-Guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project. American journal of kidney diseases: the official journal of the National Kidney Foundation 2017, 69(5):658–666.